Phaseline

Targets › AVP

AVP (Vasopressin-neurophysin 2-copeptin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine.

Precursor of Arg-vasopressin, an antidiuretic hormone, and neurophysin 2, its carrier protein..; FUNCTION: [Arg-vasopressin]: Has a direct antidiuretic action on the kidney, it also causes vasoconstriction of the peripheral vessels. Acts by binding to vasopressin receptors (V1bR/AVPR1B, V1aR/AVPR1A, and V2R/AVPR2)..; FUNCTION: [Neurophysin 2]: Carrier protein that binds to and transports Arg-vasopressin from the…. (UniProt, P01185)

Open in Phaseline: the race on AVP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assistance Publique - Hôpitaux de ParisArginine-vasopressin (AVP)
Vasopressin V1 and V2 receptor agonist
AVPPhase 3Postresuscitation Syndrome–

Conditions

Postresuscitation Syndrome (1)

Modalities

small molecule (1)

Companies

Assistance Publique - Hôpitaux de Paris (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.